Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Recruiting now · Early Phase 1

Conditions studied: Prostate Cancer

In brief

The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease. In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy data) will not be targeted and receive only fall-off dose, which we have shown to be associated with reductions in toxicity.

Key facts

Study ID
NCT03861676
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed
20
Starts
2023-08-03
Expected to finish
2033-12-01
Last updated by the study team
2026-02-13

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.